Neurofibroma epidemiology and demographics

Revision as of 16:15, 1 November 2019 by Aelsaiey (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Neurofibroma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neurofibroma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neurofibroma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neurofibroma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neurofibroma epidemiology and demographics

CDC on Neurofibroma epidemiology and demographics

Neurofibroma epidemiology and demographics in the news

Blogs on Neurofibroma epidemiology and demographics

Directions to Hospitals Treating Neurofibroma

Risk calculators and risk factors for Neurofibroma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2], Shanshan Cen, M.D. [3]

Overview

Neurofibroma usually occurs between 20-40 years of age, and affects men and women equally. However, plexiform neurofibromas are thought to be congenital defects, hence, they occur earlier in life.

Epidemiology and Demographics

Age

Gender

References


Template:WikiDoc Sources